Hong Kong Stock Movement: GUANZE MEDICAL surged 25.86%

Hong Kong Stock Movement Stocks with High Trading Volume in the Industry YaoShiBang rose by 6.63%. Based on recent important news: On September 29, Tianfeng Securities released a research report, maintaining a "Buy" rating for YaoShiBang and raising the forecast for net profit attributable to the parent company for 2025-2027. The company's platform and self-operated business performed steadily, with breakthroughs in its own brand business, driving the stock price up. Data source: Zhitong Finance. On September 29, YaoShiBang achieved operating revenue of 9.843 billion yuan in H1 2025, a year-on-year increase of 11.66%; net profit attributable to the parent company was 78 million yuan, a year-on-year increase of 258.01%. The company's cash flow continues to show net inflow, with ample cash reserves, enhancing market confidence. Data source: Jinwu Finance. Industry volatility risks need attention. China National Pharmaceutical Group rose by 0.05%. Based on recent important news: On September 29, Lazard Asset Management LLC reduced its holdings in China National Pharmaceutical Group by 546,400 shares, leading to a certain impact on market confidence in the stock, with increased trading volume. Data source: Hong Kong Stock Exchange. On September 28, the first quadrivalent human papillomavirus vaccine under China National Pharmaceutical Group was approved for market launch, driving the stock price up. Data source: Official WeChat account of China National Pharmaceutical. On September 28, China National Pharmaceutical achieved significant growth in the SPD project, with medical device revenue increasing by 13% year-on-year, enhancing market expectations for the company's future growth. Data source: Zhongcheng Medical Devices. The pharmaceutical industry is transforming, with policy support for growth. Health 160 rose by 1.46%. According to recent important news: On September 29, Health 160 announced the appointment of non-executive director Ms. Sun Meng and independent non-executive director Mr. Zou Jun as members of the nomination committee. This personnel change may enhance the company's governance structure, boost market confidence, and drive the stock price up. Data source: Zhitong Finance. Industry trends are stable, with significant capital inflow. Stocks with High Market Capitalization in the Industry Shanghai Pharmaceuticals rose by 0.08%. According to recent important news: On September 28, the pharmaceutical commercial sector is experiencing a painful transformation from "channel supremacy" to "value creation." With the promotion of the SPD model and rapid growth in the out-of-hospital market, companies like Shanghai Pharmaceuticals are actively laying out new businesses to enhance supply chain management capabilities and deepen customer binding. This transformation may bring new growth points for the company, driving a slight increase in stock price. Source: Zhongcheng Medical Devices. The pharmaceutical industry is transforming, focusing on the out-of-hospital market